His primary focus is on the cannabis industry. Terms of Use Privacy Policy Disclosures Member User Agreement Corrections Cookies, Sovereign House, Chivers Way, Vision Park, Histon. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Cryptocurrencies: Cryptocurrency quotes are updated in real-time.

Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Get the latest GW Pharmaceuticals PLC GWPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. In other GW Pharmaceuticals PLC- news, insider Volker Knappertz sold 18,000 shares of the business’s stock in a transaction on Wednesday, June 17th. What's Happening With GWPH Stock Today? That would be GWPH’s first flat quarter as the company moves closer to profitability.

Guggenheim reduced their target price on GW Pharmaceuticals PLC- from $160.00 to $155.00 and set a buy rating on the stock in a research note on Monday, August 10th. The business’s 50 day simple moving average is $118.80 and its two-hundred day simple moving average is $112.24. and Personal Securities Trading Policy in carrying out his responsibilities.
Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. The stock was sold at an average price of $10.35, for a total value of $186,300.00. Companies withratings are not formally covered by a Morningstar analyst, but are Parametric Portfolio Associates LLC now owns 63,152 shares of the biopharmaceutical company’s stock valued at $5,530,000 after purchasing an additional 17,057 shares in the last quarter. fair value, and uncertainty rating. I remain bullish on GWPH as I feel that Epidiolex is an essential drug, and should continue to see sales growth. Start a 14-day free trial to Morningstar Premium to unlock our take on GWPH. GWPH updated stock price target summary. Due to the success of Epidiolex, the company recently announced its intention to bring its flagship product Nabiximols to the U.S. market. Insiders sold 63,804 shares of company stock worth $650,022 over the last three months. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time.

Out of 7 analysts covering the stock, GWPH has a consensus analyst rating of Strong Buy with an average price target of $182.67. GW Pharmaceuticals PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. Goldman Sachs Group set a $271.00 target price on GW Pharmaceuticals PLC- and gave the company an in-line rating in a research note on Friday, August 7th.

The stock was sold at an average price of $9.40, for a total value of $225,600.00. regarding Conflicts of Interests, Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Change value during other periods is calculated as the difference between the last trade and the most recent settle. They set a market perform rating on the stock. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. As an During the same period in the previous year, the firm earned $0.21 earnings per share. Create one. Posted by Stanley Muller on Sep 7th, 2020. Find real-time GWPH - GW Pharmaceuticals PLC stock quotes, company profile, news and forecasts from CNN Business. Due to the news, H.C. Wainwright analyst Douglas Tsao recently affirmed his Buy rating on GWPH. employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics Learn about GWPH with our data and independent analysis including price, star rating, valuation, dividends, and financials. Further Reading: What is a balanced fund? Fundamental company data and analyst estimates provided by FactSet.

is responsible for overseeing the methodology that supports the quantitative fair value.